HomeAI · summaries
Storia in 5 fonti
Silence spells out Phase 2 success for gene-silencing drug in rare blood cancer
Silence Therapeutics' divesiran hits its Phase 2 target in polycythemia vera, setting up a Phase 3 trial
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia…
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
- ·
statnews.com
Silence Therapeutics aims at Takeda with new data in rare blood cancer
A rare blood cancer drug from Silence Therapeutics showed strong results in a trial, potentially setting it up to compete with a Takeda medicine.
